急诊科无肌钙蛋白检测识别低危胸痛:HE-MACS与HEAR风险评分的验证研究
本研究对Limit of Detection and ECG discharge strategy随机对照试验数据集(n=629,2018年6月至2019年3月,8家英国医院)进行事后分析,计算HEAR和HE-MACS评分。以HE-MACS 30天主要不良心脏事件(MACE)风险<4%、HEAR评分<2定义适合出院的「极低危」患者。30天内MACE发生于42/629(7%)。HE-MACS和HEAR分别识别85/629和181/629例为极低危,其中MACE分别发生0/85和1/181例;HE-MACS排除MACE的敏感性为100%(95%CI 91.6%至100%),HEAR为97.6%(95%CI 87.7%至99.9%)。作者认为两评分有潜力作为无需肌钙蛋白的急性心肌梗死排除工具,但需前瞻性研究进一步验证。
要点
- HE-MACS以30天MACE风险<4%定义极低危,识别85/629例,其中0/85例发生MACE,排除MACE敏感性100%(95%CI 91.6%至100%)。
- HEAR以评分<2定义极低危,识别181/629例,其中1/181例发生MACE,排除MACE敏感性97.6%(95%CI 87.7%至99.9%)。
- 30天内MACE发生于42/629(7%)的队列。
- 评分中的就诊症状预测力差,仅出汗达到统计学显著(OR 4.99,95%CI 2.33至10.67)。
- 传统心血管危险因素和临床医生怀疑与30天MACE存在相关。
适用人群与场景
- 因可能心源性胸痛就诊于急诊科的患者(数据来自8家英国医院,2018年6月至2019年3月)。
诊断标准与关键阈值
- HE-MACS评分对应的30天MACE风险<4%定义为「极低危」,适合出院。
- HEAR评分<2定义为「极低危」,适合出院。
研究设计与关键结果
- 研究类型:对Limit of Detection and ECG discharge strategy随机对照试验数据集的事后分析;样本量n=629;8家英国医院;2018年6月至2019年3月。
- 30天内MACE发生于42/629(7%)的队列。
- HE-MACS识别85/629例为极低危,其中MACE发生0/85例;HEAR识别181/629例为极低危,其中MACE发生1/181例。
- HE-MACS排除MACE的敏感性为100%(95%CI 91.6%至100%);HEAR为97.6%(95%CI 87.7%至99.9%)。
- 评分中的就诊症状预测力差,仅出汗达到统计学显著(OR 4.99,95%CI 2.33至10.67)。
- 传统心血管危险因素和临床医生怀疑与30天MACE存在相关。
证据类型、等级与局限
- 证据类型:对随机对照试验数据集的事后分析(验证研究)。
- 局限:原文报告需前瞻性研究进一步验证这些评分。
对床旁实践的改变
- 作者认为HEAR和HE-MACS有潜力作为无需肌钙蛋白检测的急性心肌梗死排除工具。
- 作者指出需前瞻性研究进一步验证这些评分。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Patients presenting to EDs with chest pain of possible cardiac origin represent a substantial and challenging cohort to risk stratify. Scores such as HE-MACS (History and Electrocardiogram-only Manchester Acute Coronary Syndromes decision aid) and HEAR (History, ECG, Age, Risk factors) have been developed to stratify risk without the need for troponin testing. Validation of these scores remains limited.
METHODS: We performed a post hoc analysis of the Limit of Detection and ECG discharge strategy randomised-controlled trial dataset (n=629; June 2018 to March 2019; 8 UK hospitals) to calculate HEAR and HE-MACS scores. A <4% risk of major adverse cardiac events (MACE) at 30 days using HE-MACS and a score of <2 calculated using HEAR defined 'very low risk' patients suitable for discharge. The primary outcome of MACE at 30 days was used to assess diagnostic accuracy.
RESULTS: MACE within 30 days occurred in 42/629 (7%) of the cohort. HE-MACS and HEAR scores identified 85/629 and 181/629 patients as 'very low risk', with MACE occurring in 0/85 and 1/181 patients, respectively. The sensitivities of each score for ruling out MACE were 100% (95% CI: 91.6% to 100%) for HE-MACS and 97.6% (95% CI: 87.7% to 99.9%) for HEAR. Presenting symptoms within these scores were poorly predictive, with only diaphoresis reaching statistical significance (OR: 4.99 (2.33 to 10.67)). Conventional cardiovascular risk factors and clinician suspicion were related to the presence of MACE at 30 days.
CONCLUSION: HEAR and HE-MACS show potential as rule out tools for acute myocardial infarction without the need for troponin testing. However, prospective studies are required to further validate these scores.
参考来源
- Todd F, Duff J, Carlton E, et al. Identifying low-risk chest pain in the emergency department without troponin testing: a validation study of the HE-MACS and HEAR risk scores. Emerg Med J. 2021. PMID: 34753776. doi:10.1136/emermed-2021-211669
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。